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Abstract
Background: Genome-wide association studies have revealed an association between several loci in the nicotinic
acetylcholine receptor gene cluster CHRNA5-A3-B4 and daily cigarette consumption. Recent studies have sought to
refine this phenotype, and have shown that a locus within this cluster, marked primarily by rs1051730 and
rs16969968, is also associated with levels of cotinine, the primary metabolite of nicotine. This association remains
after adjustment for self-reported smoking, which suggests that even amongst people who smoke the same number of
cigarettes there is still genetically-influenced variation in nicotine consumption. This is likely to be due to differences in
smoking topography, that is, how a cigarette is smoked (e.g., volume of smoke inhaled per puff, number of puffs taken
per cigarette). The aim of this study is to determine potential mediation of the relationship between the rs1051730
locus and cotinine levels by smoking topography.
Methods/Design: Adopting a recall-by-genotype design, we will recruit 200 adults from the Avon Longitudinal Study
of Parents and Children on the basis of minor or major homozygote status at rs1051730 (100 in each genotype group).
All participants will be current, daily smokers. Our primary study outcome measures will be measures of smoking
topography: total volume of smoke (ml) inhaled per cigarette, total volume of smoke (ml) inhaled over of the
course of one day, and salivary cotinine level (ng/ml).
Discussion: This study will extend our understanding of the biological basis of inter-individual variability in
heaviness of smoking, and therefore in exposure to smoking-related toxins. The novel recall-by-genotype
approach we will use is efficient, maximising statistical power, and enables the collection of extremely precise
phenotypic data that are impractical to collect in a larger sample. The methods described within this protocol
also hold the potential for wider application in the field of molecular genetics.
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Background
Twin and adoption studies have provided consistent evi-
dence that genetic factors contribute to the aetiology of
cigarette smoking, including smoking initiation, progres-
sion to heavy use and persistence [1-5]. Advances in the
identification of specific genetic variants associated with
these phenotypes are now being made, principally
through the application of genome-wide technologies.
Genome-wide association (GWA) consortia comprising
multiple cohorts/studies, and large sample sizes (often
in excess of 50,000), are becoming increasingly com-
mon, with large sample sizes offering increased power
to detect the small genetic effects common in complex
diseases. Requiring no a priori hypotheses, these stud-
ies have been successful in determining novel variants
associated with disease, including smoking-related
behaviours [6].
GWA studies have provided robust evidence of an
association between several loci in the nicotinic acetyl-
choline receptor gene cluster CHRNA5-A3-B4 (located
on the long arm of chromosome 15) and heaviness of
smoking [6-8]. One locus within this gene cluster,
marked principally by variants rs1051730 in CHRNA3
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and rs16969968 in CHRNA5 (which are almost perfectly
correlated in European populations and therefore essen-
tially interchangeable), has generated particular interest,
and has led to renewed interest in these gene products.
Research using knock-out mouse models suggests that
that locus influences self-titrated nicotine exposure via
effects at receptors which influence toxicity of high doses
of nicotine [9].
The GWA studies described above employed relatively
crude measures of smoking heaviness, namely self-reported
daily cigarette consumption. This is often necessary given
the need to harmonise phenotype definitions across studies.
Objective, precise measures of heaviness of smoking (e.g.,
levels of cotinine, the primary metabolite of nicotine, or
other tobacco metabolites) show a much stronger asso-
ciation with rs1051730 than measures of self-reported
heaviness of smoking [10,11]. Munafò and colleagues
[12] recently showed a much stronger association of
rs1051730 with cotinine level compared to self-reported
cigarette consumption. They also showed that the asso-
ciation with cotinine is robust to adjustment for self-
reported daily cigarette consumption. This suggests that
even among equal cigarette consumers there is genetic-
ally influenced variation in total nicotine exposure.
Munafò and colleagues [12] argue that this is likely to
be due to differences in smoking topography, that is,
how a cigarette is smoked (number of puffs taken per
cigarette, volume of smoke inhaled per puff, and so on).
It is now well-established that smokers modify their
smoking behaviour to self-titrate circulating nicotine
to a level appropriate to their need [13,14]. Here we
present a protocol to determine potential mediation of
the relationship between rs1051730/rs16969968 and
cotinine levels by smoking topography. The results of
this study will determine whether the stronger associ-
ation observed between this variant and cotinine levels
(compared to daily cigarette consumption) is mediated
via self-regulation of nicotine exposure. This study will
extend our understanding of the biological underpinnings
of inter-individual variability in heaviness of smoking, and
resulting exposure to smoking related toxins.
Methods/Design
Study design
A recall-by-genotype design will be employed, whereby
a genetic variant delivering functional change (in this
case rs1051730/rs16969968) is used to select partici-
pants for further assessment of detailed, clinically-rele-
vant, phenotypes.
Participants and recruitment
We will prospectively recruit 200 mothers and children
from the Avon Longitudinal Study of Parents and Children
(ALSPAC; http://www.bristol.ac.uk/alspac/) on the basis of
minor or major homozygote status at rs1051730 (100 in
each genotype group). All participants will be current,
daily smokers (of manufactured cigarettes), in good
health. Smoking status will be confirmed during initial
screening by a carbon monoxide (CO) breath reading. If
this reading is below 10 ppm then a urinary cotinine as-
sessment (yielding a positive or negative result) will also
be used to determine smoking status. Participants will
be reimbursed for their time with £50 worth of shop-
ping vouchers on completion of the study.
Inclusion criteria
 Aged 21 years or over;
 Current, daily smoker (of manufactured cigarettes);
 Minor or major homozygote status at rs1051730/
rs16969968;
 In good physical and mental health;
 Able to give informed consent as judged by the
investigator.
Exclusion criteria
 Non-smoker;
 Current substance dependence (other than nicotine
and caffeine);
 Significant current or past illness;
 Currently pregnant or lactating.
Ethical considerations and informed consent
Full ethics approval for this study was granted by the
ALSPAC Ethics and Law Committee. All potential par-
ticipants will be issued with an information sheet prior
to commencing the study, detailing the purpose and na-
ture of the study. They will also be given the opportunity
to raise any questions with the investigators prior to
making a decision to participate. Participants will be in-
formed that they are free to withdraw from the study at
any time.
Sample size determination
Our total sample will consist of 200 participants (100 in
each of the two genotype groups). Studies of rs1051730
and heaviness of smoking using cigarettes per day indi-
cate a per-allele effect equivalent to approximately one
cigarette per day [15]. Assuming a 10 cigarettes/day
smoker, we extrapolate that this will correspond to a
70 ml difference in volume inhaled per cigarette, given
an average inhaled volume of 700 ml (SD ~200 ml)
based on pilot data. An effect of this magnitude will be
detectable with 70% power (α = 0.05) in the present
study. Studies of rs1051730 and heaviness of smoking
using cotinine level indicate a per-allele effect equivalent
to a 24.4 ng/ml increase in serum/plasma cotinine level
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[12]. An effect of this magnitude will be detectable with
80% power (α = 0.05) in the present study.
Measures and materials
Smoking topography will be assessed using a smoking top-
ography monitor (CReSS Pocket, Borgwaldt KC, Hamburg,
Germany). This is a self-contained, battery-operated device,
which measures smoking behaviour, with time and date
tags assigned at cigarette insertion/removal, providing a
highly quantitative view of cigarette smoking behaviour.
Data captured include: puff volume; puff duration; puff
flow; puffs per cigarette; inter-puff interval; time to first
puff; time to removal; volume per cigarette. Onboard
memory is used to store all measures, enabling ambula-
tory monitoring outside of the laboratory.
Smoking topography will be assessed both in the la-
boratory and in the participants’ ‘natural’ environment
over the course of one day. Primary outcome measures
for smoking topography will be total volume of tobacco
smoke consumed per cigarette (ml) and per day (ml).
The cigarette smoked in the laboratory will serve additional
purposes. Firstly, it will allow participants the opportunity
to become familiar with use of the monitor whilst assist-
ance is available. Secondly, it will allow determination of
the impact of a single cigarette smoked under controlled
conditions on cardiovascular and affect measures.
Cotinine levels will be assessed from saliva. Saliva samples
will be collected using salivettes (Sarstedt, Nümbrecht,
Germany). Samples will be centrifuged twice (at 5800 rpm
for 15 minutes) within 24 hours of collection to ensure re-
moval of human tissue, frozen (at −30°C) and then sent to
ABS Laboratories Ltd. for quantitative analysis of cotinine
content.
The Fagerström Test of Nicotine Dependence (FTND)
[16] will be used to determine level of nicotine dependence.
The Brief Questionnaire of Smoking Urges (QSU-Brief)
[17,18] and the Positive and Negative Affect Scale (PANAS)
[19] will be administered pre- and post- cigarette smoking
in the laboratory to assess craving and affect respectively.
Cardiovascular measures (blood pressure and heart
rate) will be assessed using the OMRON M6 blood pres-
sure monitor (OMRON Healthcare, UK). Carbon mon-
oxide levels will be assessed using a PiCO + Smokerlyzer
(Bedfont Scientific, UK).
Genotyping of rs1051730 has previously been under-
taken by KBioscience Ltd. (www.kbioscience.co.uk), who
use a proprietary competitive allele specific PCR system
(KASPar) for single nucleotide polymorphism analysis.
Primary outcome measures
 Total volume of smoke inhaled per cigarette (ml),
and per day (ml);
 Saliva cotinine level (ng/ml).
Secondary outcome measures
 Number of cigarettes consumed per day (self-reported
and objectively assessed);
 Heart rate and blood pressure (pre- and post-cigarette
consumption);
 Craving scores (pre- and post-cigarette consumption);
 Positive and negative affect scores (pre- and post-
cigarette consumption).
Procedure
The study will take place over the course of three days
(see Figure 1). On day one participants will attend the
research centre for approximately 45 minutes. An infor-
mation sheet will be provided, and written, informed
consent obtained. Smoking status will be confirmed by
a CO reading and/or urinary cotinine assessment, as
described. Questionnaires will then be used to obtain
demographic information, smoking history, and level of
nicotine dependence. A saliva sample will then be col-
lected for quantitative assessment of cotinine level. Partici-
pants will next be introduced to the smoking topography
monitor, and issued with instructions regarding its use.
Pre-cigarette PANAS and QSU-Brief questionnaires will
be completed, and cardiovascular measures assessed
(blood pressure and heart rate). Participants will then
be asked to smoke one of their own cigarettes using the
smoking topography monitor. This will take place in a
ventilated cubicle, under observation by the investigator
through one-way glass. The participant will be able to
speak to the investigator via an intercom system during
the procedure. Post-cigarette PANAS and QSU-Brief
questionnaires will then be completed, and cardiovascu-
lar measures again assessed. At the end of this session,
the participant will be issued with a smoking topography
monitor, alongside an information sheet regarding its use
and care. On day two, participants will use the smoking
topography monitor for each cigarette consumed that day
in their natural environment. On day three, participants
will return to the research centre to return the device or, if
more convenient, the researcher will visit the participant’s
home address to collect it. Following this, participants will
be reimbursed and a debrief sheet outlining the aims of
the study will be issued.
Statistical plan
Firstly, we will examine the effect of rs1051730 genotype
on cotinine level, seeking to confirm the previously ob-
served relationship. Secondly, we will examine the effect
of rs1051730 genotype on smoking topography outcome
measures (namely volume of smoke inhaled per cigarette
and per day). Finally, we will examine the effect of
rs1051730 genotype on cotinine level whilst adjusting
for smoking topography outcome measures. This will be
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contrasted with the same association adjusted for self-
reported daily cigarette consumption. Multiple regres-
sion will be used in all instances, including age and sex
as covariates in a forced entry model.
Discussion
Here we describe a study to investigate potential medi-
ation of the relationship between a locus in the CHRNA5-
A3-B4 gene cluster (rs1051730/rs16969968) and salivary
cotinine levels by smoking topography. This study dir-
ectly builds upon previous research which has shown
that this locus is associated with objective measures
of heaviness of smoking (cotinine level), even amongst
equivalent cigarette consumers based on self-report
measures [12]. It will extend our understanding of the
biological basis of inter-individual variability in heavi-
ness of smoking, and therefore in exposure to smoking-
related toxins.
The study employs a recall-by-genotype design, whereby
a genetic variant delivering functional change (in this case
rs1051730/rs16969968) is used to select participants (or
their biological samples) for further detailed, clinically-
relevant, phenotype examination. This novel, innovative
approach is warranted for two main reasons. Firstly, it is
efficient. In situations where it is necessary to measure
expensive phenotypes in order to clarify the nature of a
genetic association, statistical power can be improved by
using genotype-specific recall instead of random sampling.
For example, it is far more powerful to selectively
phenotype 100 minor homozygotes and 100 major ho-
mozygotes (at opposite ends of a biological gradient)
than to phenotype 200 individuals selected at random,
because the latter design would recruit far fewer minor
homozygotes. Only 16% of Europeans are minor ho-
mozygotes at rs1051730 (http://hapmap.ncbi.nlm.nih.
gov/), so in an unselected sample of 200 individuals we
would expect only 32 minor homozygotes. Secondly,
recall-by-genotype studies enable the collection of ex-
tremely precise phenotypic data that would be imprac-
tical to collect in a much larger sample, given time and
expense constraints. Not only do precisely-assessed
phenotypes potentially afford increased statistical ef-
ficiency, they also afford insight into underlying mech-
anisms of association.
The recall-by-genotype approach described within this
protocol holds the potential for wider application in the
field of molecular genetics. This approach could prove
particularly useful in the intensive physiological pheno-
typing of variants found to be related to disease out-
comes, serving as a useful follow up strategy for GWA
studies (for example, see [20]).
In summary, we describe a study which will build
upon and triangulate previous research, and extend our
understanding of the biological basis of inter-individual
variability in heaviness of smoking, and therefore in
exposure to smoking-related toxins. The novel recall-
by-genotype approach we will use is efficient, maxi-
mising statistical power and enabling the collection of
extremely precise phenotypic data that are impractical
to collect in a larger sample. The methods described
within this protocol also hold the potential for wider
application in the field of molecular genetics.
Figure 1 Study procedure.
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Trial status
Recruitment for this study commenced in July 2012.
Testing is due to commence in November 2013. This
study is expected to run until July 2014.
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